Isabelle C. Van Gelder, M.D ., Hessel F. Groenveld, M.D., Harry J.G.M. Crijns, M.D., Ype S. Tuininga, M.D., Jan G.P. Tijssen, Ph.D., A. Marco Alings, M.D., Hans L. Hillege, M.D., Johanna A. Bergsma-Kadijk, M.Sc., Jan H. Cornel, M.D., Otto Kamp, M.D., Raymond Tukkie, M.D., Hans A. Bosker, M.D., Dirk J. Van Veldhuisen, M.D., and Maarten P. Van den Berg, M.D. For the Competition II Investigators: Lenient versus Strict Price Control in Patients with Atrial Fibrillation Atrial fibrillation is not a benign condition.1 It may trigger symptoms and is associated with stroke and center failure.

Quartile 1 of 0.90 , an odds ratio for quartile 3 vs. Quartile 1 of 0.88 , and an odds ratio for quartile 4 vs. Quartile 1 of 0.74 . Height-Associated Variants and Cardiovascular Risk Elements The findings from the analyses of the composite association between height-associated variants and specific cardiovascular risk factors are provided in Table 1. For some of the risk factors, the analyses didn’t identify any proof a link between genetically determined elevation and the risk of CAD. Both exceptions had been LDL cholesterol and triglyceride levels, for which there were small but significant associations. For both LDL cholesterol and triglycerides, the associations were in a path that could have contributed to the observed association between a shorter genetically determined height and an increased risk of CAD.